Synapse - Works

Results (4925)

Nivolumab (nivo) in combination with radiotherapy (RT) +/- temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Meeting Abstract

Lim, M.; Omuro, A.; Vlahovic, G.; Reardon, D. A.; Sahebjam, S.; Cloughesy, T.; Baehring, J.; Butowski, N.; Potter, V.; Zwirtes, R.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

A single-arm, phase ii study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)

Meeting Abstract

McArthur, H. L.; Barker, C. A.; Gucalp, A.; Lebron Zapata, L.; Wen, Y. H.; Phung, A.; Wilgucki, M.; Henrich, M.; Arnold, B. B.; Zhang, Z.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

BEACON CRC: Safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

Meeting Abstract

Huijberts, S.; Schellens, J. H. M.; Elez, E.; Cuyle, P. J.; Van Cutsem, E.; Yaeger, R.; Fakih, M.; Montagut, C.; Peeters, M.; Desai, J.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

Meeting Abstract

Grob, J. J.; Schadendorf, D.; Wagstaff, J.; Márquez-Rodas, I.; Lebbé, C.; Ascierto, P. A.; Hodi, F. S.; Grossmann, K.; Hassel, J. C.; Walker, D.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N + I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups

Meeting Abstract

Escudier, B.; Tannir, N. M.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Plimack, E. R.; Barthelemy, P.; George, S.; Neiman, V.; Porta, C.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN)

Meeting Abstract

Ferris, R. L.; Gonçalves, A.; Baxi, S. S.; Martens, U. M.; Gauthier, H.; Langenberg, M.; Spanos, W. C.; Leidner, R. S.; Kang, H.; Russell, J.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors

Meeting Abstract

Garcia-Corbacho, J.; Spira, A.; Boni, V.; Feliu, J.; Middleton, M.; Burris, H.; Yang Weaver, A.; Will, M.; Harding, J.; Meric-Bernstam, F.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status

Meeting Abstract

Grivas, P.; Plimack, E.; Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Bellmunt, J.; Powles, T.; Hahn, N.; de Wit, R.; Bajorin, D.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry

Meeting Abstract

Francini, E.; Yip, S.; Ahmed, N. S.; Li, H.; Ardolino, L.; Evan, C. P.; Kaymakcalan, M.; Shaw, G. K.; Kantoff, P.; Taplin, M. E.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save